NovaBay Pharmaceuticals Announces DERMAdoctor’s KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to be Featured on QVC at a Special Price
12 6월 2023 - 7:50PM
Business Wire
Chief Product Officer Dr. Audrey Kunin to
showcase KP Duty combo with supercharged exfoliators and
moisturizers to help rapidly lift away dry, rough bumps and reveal
healthier looking skin
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces that Chief Product Officer Dr.
Audrey Kunin will appear on QVC®’s Girls Night In with Courtney
& Jane on Tuesday, June 13, 2023 at 10:00 p.m. Eastern time to
showcase DERMAdoctor®’s system for dry, rough, bumpy skin. The
two-piece Ultra Duo set of KP Duty Scrub and KP Duty Lotion, both
in the 8-ounce size, will be available at QVC for a special price
of $56.50.
“Our KP Duty Ultra Duo is specially formulated as a two-step
system to help temporarily exfoliate, smooth, and hydrate dry,
rough, and bumpy skin on the body, together with moisturizers to
help hydrate for softer, more supple and smoother looking skin,”
said Dr. Audrey Kunin, a board-certified dermatologist. “Like all
DERMAdoctor products, KP Duty Scrub and KP Duty Lotion are
dermatologist tested to be non-irritating and ideal for year-round
use.”
KP Duty Body Scrub is formulated with a 10% complex of
Alpha Hydroxy Acids and Polyhydroxy Acids for a dual action
physical and chemical exfoliation of the skin that temporarily
removes the dead surface skin cells, and a hydrating botanical
blend of Evening Primrose, Black Currant Seed Oil, Borage Seed Oil,
and White Tea Leaf Extract.
KP Duty Lotion is formulated with a 10% complex of Alpha
Hydroxy Acids and Polyhydroxy Acids to temporarily exfoliate the
skin to help alleviate skin roughness and improve the appearance of
skin texture and smoothness, along with ceramides, botanicals and
the humectant Urea to help temporarily hydrate and moisturize the
skin.
Dr. Audrey Kunin is an author, clinician, educator, television
personality and recognized trailblazer in the skincare industry.
DERMAdoctor delivers on the promise that skin therapy can be simple
and easy. All DERMAdoctor products are scientifically formulated to
provide measurable results for common skincare concerns.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our products,
business strategies, current partnerships, marketing efforts, and
any future revenue that may result from such partnerships and
related marketing initiatives, as well as generally the Company’s
expected future financial results. These statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612005019/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
NovaBay Pharmaceuticals (AMEX:NBY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024